| scholarly article | Q13442814 |
| P50 | author | Harald Mischak | Q37828676 |
| Lise Tarnow | Q41581995 | ||
| Peter Rossing | Q45354617 | ||
| Petra Zürbig | Q61800394 | ||
| Kasper Rossing | Q112735798 | ||
| P2093 | author name string | Bruce A Julian | |
| Jan Novak | |||
| Joshua J Coon | |||
| David M Good | |||
| Mohammed Dakna | |||
| PREDICTIONS Network | |||
| P2860 | cites work | Clinical proteomics: A need to define the field and to begin to set adequate standards | Q40247421 |
| An imbalance between matrix metalloproteinase-2 and tissue inhibitor of matrix metalloproteinase-2 contributes to the development of early diabetic nephropathy | Q40275139 | ||
| Impact of diabetic nephropathy and angiotensin II receptor blockade on urinary polypeptide patterns | Q46545493 | ||
| Occurrence of type VI collagen in extracellular matrix of renal glomeruli and its increase in diabetes | Q46650313 | ||
| Electrophoretic methods for analysis of urinary polypeptides in IgA-associated renal diseases | Q46899149 | ||
| Proteomic patterns established with capillary electrophoresis and mass spectrometry for diagnostic purposes | Q47588320 | ||
| Glomerular expression of CTGF, TGF-beta 1 and type IV collagen in diabetic nephropathy. | Q53582462 | ||
| Urinary Proteomic Biomarkers in Coronary Artery Disease | Q56970751 | ||
| Urine protein patterns can serve as diagnostic tools in patients with IgA nephropathy | Q57712178 | ||
| Proteomic analysis for the assessment of diabetic renal damage in humans | Q57712216 | ||
| Causes of albuminuria in patients with type 2 diabetes without diabetic retinopathy | Q73024377 | ||
| Combined effects of moderately elevated blood glucose and locally produced TGF-beta1 on glomerular morphology and renal collagen production | Q80201062 | ||
| Peptide and protein sequence analysis by electron transfer dissociation mass spectrometry | Q24561920 | ||
| Feature selection and nearest centroid classification for protein mass spectrometry | Q24811562 | ||
| Advanced glycation end-product cross-link breakers. A novel approach to cardiovascular pathologies related to the aging process | Q28298880 | ||
| The minimum information about a proteomics experiment (MIAPE) | Q29615391 | ||
| Electron transfer dissociation of peptide anions | Q30436891 | ||
| CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics | Q30437141 | ||
| Pilot study of capillary electrophoresis coupled to mass spectrometry as a tool to define potential prostate cancer biomarkers in urine | Q30437217 | ||
| Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis | Q30439686 | ||
| Alterations in the renal elastin-elastase system in type 1 diabetic nephropathy identified by proteomic analysis | Q33198532 | ||
| Biomarker discovery by CE-MS enables sequence analysis via MS/MS with platform-independent separation | Q33241474 | ||
| High-resolution proteome/peptidome analysis of peptides and low-molecular-weight proteins in urine | Q33610197 | ||
| Capillary electrophoresis-mass spectrometry as a powerful tool in clinical diagnosis and biomarker discovery | Q34400055 | ||
| Predicting the clinical outcome of congenital unilateral ureteropelvic junction obstruction in newborn by urinary proteome analysis | Q34503824 | ||
| Crosslink breakers: a new approach to cardiovascular therapy | Q35817743 | ||
| Receiver-operating characteristic analysis for evaluating diagnostic tests and predictive models | Q36729392 | ||
| Advances in urinary proteome analysis and biomarker discovery | Q36747925 | ||
| Body fluid proteomics for biomarker discovery: lessons from the past hold the key to success in the future | Q36985811 | ||
| P4510 | describes a project that uses | SQL | Q47607 |
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1283-1290 | |
| P577 | publication date | 2008-04-30 | |
| P1433 | published in | Journal of the American Society of Nephrology | Q17123893 |
| P1476 | title | Urinary proteomics in diabetes and CKD | |
| P478 | volume | 19 |
| Q26769678 | A Systems Biology Overview on Human Diabetic Nephropathy: From Genetic Susceptibility to Post-Transcriptional and Post-Translational Modifications |
| Q34424829 | A comprehensive map of the human urinary proteome |
| Q28478586 | A distinct urinary biomarker pattern characteristic of female Fabry patients that mirrors response to enzyme replacement therapy |
| Q46945275 | A meta-analysis of expression signatures in glomerular disease |
| Q35579632 | A tool for biomarker discovery in the urinary proteome: a manually curated human and animal urine protein biomarker database |
| Q44319128 | A urinary peptide biomarker set predicts worsening of albuminuria in type 2 diabetes mellitus. |
| Q33436829 | Adapting mass spectrometry-based platforms for clinical proteomics applications: The capillary electrophoresis coupled mass spectrometry paradigm |
| Q38805683 | Adsorption of urinary proteins on the conventionally used urine collection tubes: possible effects on urinary proteome analysis and prevention of the adsorption by polymer coating |
| Q37551660 | Advances in urinary proteome analysis and biomarker discovery in pediatric renal disease |
| Q41640455 | An Optimized Method for Protein Extraction from OCT-Embedded Human Kidney Tissue for Protein Quantification by LC-MS/MS Proteomics |
| Q26774178 | An Update on the Use of Animal Models in Diabetic Nephropathy Research |
| Q36531291 | An individual urinary proteome analysis in normal human beings to define the minimal sample number to represent the normal urinary proteome |
| Q33575004 | Application of Proteomic Analysis to Renal Disease in the Clinic |
| Q37622063 | Application of proteomic analysis to the study of renal diseases |
| Q27010368 | Applications of urinary proteomics in biomarker discovery |
| Q48092320 | Applying proteomics to diagnosis of diabetic kidney disease |
| Q38290083 | Biomarkers in diabetic nephropathy: Present and future |
| Q39368726 | Biomarkers of Renal Function: Towards Clinical Actionability |
| Q41534193 | Biomarkers that predict diabetic nephropathy: the long road from finding targets to clinical use. |
| Q55304599 | Biomarkers to Assess Right Heart Pressures in Recipients of a Heart Transplant: A Proof-of-Concept Study. |
| Q36898947 | Biomarkers, the molecular gaze and the transformation of cancer survivorship |
| Q38553924 | Body fluid peptide and protein signatures in diabetic kidney diseases |
| Q37833587 | CE-MS in biomarker discovery, validation, and clinical application |
| Q34729912 | CKD273, a new proteomics classifier assessing CKD and its prognosis |
| Q38340351 | Capillary zone electrophoresis on-line coupled to mass spectrometry: A perspective application for clinical proteomics |
| Q31148183 | Classical MALDI-MS versus CE-based ESI-MS proteomic profiling in urine for clinical applications |
| Q37945790 | Clinical application of urinary proteomics/peptidomics |
| Q91130010 | Collagen turnover profiles in chronic kidney disease |
| Q36214366 | Comparison of different statistical approaches for urinary peptide biomarker detection in the context of coronary artery disease |
| Q34725022 | Comprehensive human urine standards for comparability and standardization in clinical proteome analysis |
| Q38537462 | Cost of renal replacement: how to help as many as possible while keeping expenses reasonable? |
| Q33583018 | Diabetic Nephropathy: New Risk Factors and Improvements in Diagnosis |
| Q28742785 | Diabetic nephropathy - Epidemiology in Asia and the current state of treatment |
| Q36441616 | Diabetic nephropathy: What does the future hold? |
| Q35903097 | Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides |
| Q46474917 | Diagnosis of subclinical and clinical acute T-cell-mediated rejection in renal transplant patients by urinary proteome analysis |
| Q36321624 | Differential urinary glycoproteome analysis of type 2 diabetic nephropathy using 2D-LC-MS/MS and iTRAQ quantification |
| Q30398783 | Discovery of genes related to diabetic nephropathy in various animal models by current techniques |
| Q26741494 | Early detection of diabetic kidney disease: Present limitations and future perspectives |
| Q27021632 | Early diabetic nephropathy in type 1 diabetes: new insights |
| Q33616482 | Effects of hypertension and exercise on cardiac proteome remodelling |
| Q34129628 | Evaluation of urinary biomarkers for coronary artery disease, diabetes, and diabetic kidney disease |
| Q30352538 | Evolving pandemic diabetic nephropathy |
| Q33764539 | Finding diabetic nephropathy biomarkers in the plasma peptidome by high-throughput magnetic bead processing and MALDI-TOF-MS analysis |
| Q37715627 | How to find a prognostic biomarker for progressive diabetic nephropathy |
| Q57711927 | How to get proteomics to the clinic? Issues in clinical proteomics, exemplified by CE-MS |
| Q30434677 | Identification and validation of urinary biomarkers for differential diagnosis and evaluation of therapeutic intervention in anti-neutrophil cytoplasmic antibody-associated vasculitis |
| Q92610443 | Identification of 22 novel loci associated with urinary biomarkers of albumin, sodium, and potassium excretion |
| Q51739894 | Identification of a unique urinary biomarker profile in patients with autosomal dominant polycystic kidney disease. |
| Q37460323 | Identification of urinary proteins potentially associated with diabetic kidney disease. |
| Q88740659 | Imaging mass spectrometry reveals direct albumin fragmentation within the diabetic kidney |
| Q38906256 | Implementation of CE-MS-identified proteome-based biomarker panels in drug development and patient management |
| Q47889441 | In vivo imaging of disease-modified glomerular extracellular matrix in renal disease. |
| Q35534535 | Increased DNA dicarbonyl glycation and oxidation markers in patients with type 2 diabetes and link to diabetic nephropathy |
| Q39118882 | Insights into Diabetic Kidney Disease Using Urinary Proteomics and Bioinformatics |
| Q36900310 | Isolating glomeruli from mice: A practical approach for beginners |
| Q34140378 | Left ventricular diastolic function in relation to the urinary proteome: a proof-of-concept study in a general population |
| Q33568802 | Linking transcriptomic and proteomic data on the level of protein interaction networks |
| Q44871811 | Mapping of molecular pathways, biomarkers and drug targets for diabetic nephropathy |
| Q35997377 | Mass spectrometry for diabetic nephropathy monitoring: new effective tools for physicians |
| Q34313959 | Mass spectrometry in chronic kidney disease research |
| Q34691573 | Mass spectrometry-based proteomics in Chest Medicine, Gerontology, and Nephrology: subgroups omics for personalized medicine |
| Q54098275 | Mechanism of hypertension in diabetic nephropathy. |
| Q28748796 | Multicentric validation of proteomic biomarkers in urine specific for diabetic nephropathy |
| Q34369626 | Nanoparticles that sense thrombin activity as synthetic urinary biomarkers of thrombosis. |
| Q30430034 | Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease |
| Q39094572 | Noninvasive diagnosis of chronic kidney diseases using urinary proteome analysis |
| Q40091740 | Novel Urinary Peptidomic Classifier Predicts Incident Heart Failure |
| Q28477629 | Peptide fingerprinting of Alzheimer's disease in cerebrospinal fluid: identification and prospective evaluation of new synaptic biomarkers |
| Q91755162 | Peptidomics and proteomics based on CE-MS as a robust tool in clinical application: The past, the present, and the future |
| Q26823206 | Perspectives on systems biology applications in diabetic kidney disease |
| Q33537437 | Plasma proteome analysis of patients with type 1 diabetes with diabetic nephropathy |
| Q34664488 | Poor histological lesions in IgA nephropathy may be reflected in blood and urine peptide profiling. |
| Q36300622 | Prediction of acute coronary syndromes by urinary proteome analysis |
| Q41173762 | Pro: urine proteomics as a liquid kidney biopsy: no more kidney punctures! |
| Q38553932 | Prognostic clinical and molecular biomarkers of renal disease in type 2 diabetes |
| Q38045278 | Proteome-base biomarkers in diabetes mellitus: progress on biofluids' protein profiling using mass spectrometry |
| Q37753489 | Proteomic approaches for discovering biomarkers of diabetic nephropathy. |
| Q38341211 | Proteomic biomarkers in kidney disease: issues in development and implementation |
| Q27305109 | Proteomic candidate biomarkers of drug-induced nephrotoxicity in the rat |
| Q99240980 | Proteomic characterization of obesity-related nephropathy |
| Q34330236 | Proteomic discovery of diabetic nephropathy biomarkers |
| Q30985164 | Proteomic identification of early biomarkers of acute kidney injury after cardiac surgery in children. |
| Q31105952 | Proteomic profiling of breast tissue collagens and site-specific characterization of hydroxyproline residues of collagen alpha-1-(I). |
| Q33722952 | Proteomics analysis reveals diabetic kidney as a ketogenic organ in type 2 diabetes. |
| Q38190894 | Proteomics and diabetic nephropathy: what have we learned from a decade of clinical proteomics studies? |
| Q37871572 | Proteomics in chronic kidney disease: The issues clinical nephrologists need an answer for. |
| Q30992797 | Quantitative iTRAQ-Based Proteomic Identification of Candidate Biomarkers for Diabetic Nephropathy in Plasma of Type 1 Diabetic Patients |
| Q36250869 | Quantitative proteomics reveals novel therapeutic and diagnostic markers in hypertension. |
| Q38091336 | Recent advances in capillary electrophoresis coupled to mass spectrometry for clinical proteomic applications |
| Q38114159 | Recent technological developments in proteomics shed new light on translational research on diabetic microangiopathy |
| Q45200767 | Recommendations for biomarker identification and qualification in clinical proteomics |
| Q38359455 | Renal allograft fibrosis: biology and therapeutic targets |
| Q37828116 | Renal fibrosis: insight from proteomics in animal models and human disease |
| Q36603656 | Screening for urinary biomarkers of steroid-resistant nephrotic syndrome in children |
| Q33848339 | Some views on proteomics in diabetes |
| Q33597457 | Sources of Urinary Proteins and their Analysis by Urinary Proteomics for the Detection of Biomarkers of Disease |
| Q33954585 | Successes achieved and challenges ahead in translating biomarkers into clinical applications |
| Q35619034 | Systems biology of kidney diseases |
| Q61812364 | Targeted Metabolomic Profiling of Peritoneal Dialysis Effluents Shows Anti-oxidative Capacity of Alanyl-Glutamine |
| Q37702664 | The extracellular matrix in the kidney: a source of novel non-invasive biomarkers of kidney fibrosis? |
| Q37642936 | The natural progression of kidney injury in young type 1 diabetic patients |
| Q35924547 | The renal transcriptome of db/db mice identifies putative urinary biomarker proteins in patients with type 2 diabetes: a pilot study |
| Q57956277 | The urinary proteome and metabonome differ from normal in adults with mitochondrial disease |
| Q37319249 | Tubular and glomerular injury in diabetes and the impact of ACE inhibition |
| Q61948368 | UACR—two risk markers or a 24 h collection in a minute? |
| Q55084015 | Urinary Proteome Analysis Identified Neprilysin and VCAM as Proteins Involved in Diabetic Nephropathy. |
| Q36053833 | Urinary Proteomics Pilot Study for Biomarker Discovery and Diagnosis in Heart Failure with Reduced Ejection Fraction. |
| Q38961899 | Urinary Proteomics for Diagnosis and Monitoring of Diabetic Nephropathy |
| Q35009712 | Urinary biomarkers for early diabetic nephropathy: beyond albuminuria |
| Q28475613 | Urinary collagen fragments are significantly altered in diabetes: a link to pathophysiology |
| Q57712015 | Urinary excretion of twenty peptides forms an early and accurate diagnostic pattern of acute kidney injury |
| Q39427234 | Urinary peptide-based classifier CKD273: towards clinical application in chronic kidney disease |
| Q33986978 | Urinary peptides as a diagnostic tool for renal failure detected by matrix-assisted laser desorption/ionisation mass spectrometry: an evaluation of their clinical significance. |
| Q33488868 | Urinary peptidome may predict renal function decline in type 1 diabetes and microalbuminuria |
| Q92978454 | Urinary peptidomics and bioinformatics for the detection of diabetic kidney disease |
| Q33735287 | Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria |
| Q36993564 | Urinary proteome analysis in hypertensive patients with left ventricular diastolic dysfunction |
| Q40001702 | Urinary proteome pattern in children with renal Fanconi syndrome |
| Q56970450 | Urinary proteomic biomarkers to predict cardiovascular events |
| Q38222628 | Urinary proteomics and molecular determinants of chronic kidney disease: possible link to proteases |
| Q36410737 | Urinary proteomics for early diagnosis in diabetic nephropathy |
| Q37869464 | Urinary proteomics in cardiovascular disease: Achievements, limits and hopes |
| Q48026870 | Urinary proteomics in obstructive sleep apnoea and obesity. |
| Q38943789 | Urinary proteomics using capillary electrophoresis coupled to mass spectrometry for diagnosis and prognosis in kidney diseases. |
| Q35380506 | Urine glycoprotein profile reveals novel markers for chronic kidney disease |
| Q37230698 | Urine in clinical proteomics |
| Q33698379 | Urine peptidomics for clinical biomarker discovery. |
| Q50639398 | Urine proteome analysis in heart failure with reduced ejection fraction complicated by chronic kidney disease: feasibility, and clinical and pathogenetic correlates. |
| Q33645242 | Urine proteome analysis may allow noninvasive differential diagnosis of diabetic nephropathy |
| Q84180033 | Urine proteomics and biomarkers in renal disease |
| Q37876853 | Urine proteomics in kidney and urogenital diseases: Moving towards clinical applications |
| Q34187912 | Uromodulin and α(1)-antitrypsin urinary peptide analysis to differentiate glomerular kidney diseases. |
| Q37455170 | Utility of mass spectrometry for proteome analysis: part II. Ion-activation methods, statistics, bioinformatics and annotation |
Search more.